Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 2 results out of 2
Data Insights
Renizgamglogene autogedtemcel by Editas Medicine for Beta Thalassaemia: Likelihood of Approval
Renizgamglogene autogedtemcel is under clinical development by Editas Medicine and currently in Phase II for Beta Thalassaemia. According to GlobalData,...
Data Insights
Renizgamglogene autogedtemcel by Editas Medicine for Sickle Cell Disease: Likelihood of Approval
Renizgamglogene autogedtemcel is under clinical development by Editas Medicine and currently in Phase III for Sickle Cell Disease. According to...